Equities

Corline Biomedical AB

CLBIO:STO

Corline Biomedical AB

Actions
  • Price (SEK)8.28
  • Today's Change-0.24 / -2.82%
  • Shares traded1.96k
  • 1 Year change-42.70%
  • Beta0.5580
Data delayed at least 15 minutes, as of Oct 11 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Corline Biomedical AB is a Sweden-based biotechnology company. It develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in regenerative medicine.

  • Revenue in SEK (TTM)17.55m
  • Net income in SEK-6.46m
  • Incorporated1991
  • Employees14.00
  • Location
    Corline Biomedical ABLefflersgatan 5UPPSALA 75450SwedenSWE
  • Phone+46 1 871346946
  • Fax+46 18713091
  • Websitehttps://www.corline.se/home
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lipigon Pharmaceuticals AB9.33m-20.25m38.49m----1.52--4.13-0.3541-0.35410.10120.17020.2851--0.7439---61.91-314.67-76.67-426.49-----217.15-488.14----0.00----444.4467.83------
Elicera Therapeutics AB12.07m-20.79m49.13m2.00--1.90--4.07-0.9137-0.91370.50590.73770.3224--12.856,035,610.00-55.51-40.06-79.82-49.74-----172.21-415.41----0.00--777.23--15.64------
StenoCare A/S4.76m-25.60m62.19m9.00--1.99--13.06-1.04-1.040.18681.010.0948--2.07---50.98-28.16-68.69-35.47-----537.63-371.060.6143-6.070.2763---16.30---7.77------
Odi Pharma AB (publ)22.45m355.97k63.92m--179.5628.83178.112.850.02340.02341.470.14572.1954.425.47--3.48-35.0814.86-44.272.07--1.59-99.251.221.81----15,995.75--105.16------
ExpreS2ion Biotech Holding AB8.10m-45.37m72.67m18.00--0.8097--8.97-0.7385-0.73850.13681.070.0772--6.46311,461.50-43.23-63.54-56.21-75.88-123.56-1.94-560.27-524.31----0.0065--43.07-0.156122.94--19.90--
Oncozenge AB0.00-11.78m82.81m----5.83-----1.01-1.010.001.210.00-------55.08---59.44-------------2,944.500.00------65.91------
Lipidor AB87.00k-13.53m110.62m----6.58--1,271.53-0.1505-0.15050.00090.02070.005--0.1843---77.12-59.41-178.11-75.10-----15,550.58-643.36----0.00--73.33-20.3372.24------
Vivesto AB0.00-98.92m134.51m4.00--0.7511-----0.1839-0.18390.000.33280.00----0.00-39.70---43.32--------------0.00---100.00--64.80------
Pila Pharma AB1.03m-6.92m138.89m0.00--47.31--134.32-0.3165-0.31650.0490.10820.2602--8.211,034,020.00-174.06-108.88-276.40-121.45-406.94-42.67-668.94-1,577.64---163.350.00---22.21--62.92------
Corline Biomedical AB17.55m-6.46m183.10m14.00--2.09--10.43-0.3005-0.30050.81654.070.1729--4.691,349,769.00-6.36-5.71-7.13-6.24141.25128.60-36.80-38.46---306.520.00--6.2874.14-177.67--62.51--
Enorama Pharma AB5.87m-41.41m193.83m5.00--6.55--33.03-0.9211-0.92110.12950.64080.14131.202.941,173,800.00-99.66-73.56-147.35-104.85-32.7143.36-705.54-557.422.00-29.360.0094---80.17-23.71-6.15------
Lipum AB (publ)0.00-44.17m271.52m5.00--5.49-----3.77-3.770.002.330.00----0.00-124.17-127.85-147.77-184.50-------293,228.70---423.660.0344------2.38------
Data as of Oct 11 2024. Currency figures normalised to Corline Biomedical AB's reporting currency: Swedish Krona SEK

Institutional shareholders

9.84%Per cent of shares held by top holders
HolderShares% Held
Healthinvest Partners ABas of 30 Jun 20222.12m9.84%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.